Aiforia Technologies
Provides global access to AI-powered image analysis for medical, healthcare professionals and beyond.
- B2B
- saas
- subscription
- health
- enterprise software
- health platform
- biotechnology
- deep learning
- deep tech
- artificial intelligence
- biotechnology
- horizon europe
- dt and ls
- spinout
- core ai
- ai applications
- drug development
- health it
- nordic rising star 2022
- ai drug discovery
- image recognition
- tech for hospitals and clinics
- tech for medical professionals
- techbio
- tech for biotech and pharma
- physician support tools
- medical imaging
- techbio drug discovery
- medical research
- eic
- ai for medical imaging
- top 50 nordic rising star 2022 finland
- microscope
- experiment
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | €8.0m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 24 % | 35 % | 125 % | 80 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Aiforia is a pioneering company that provides advanced software and services for pathologists, scientists, and healthcare professionals, leveraging artificial intelligence (AI) for image analysis. The company operates in the healthcare and scientific research markets, offering solutions that enhance the workflow of image analysis, whether for preclinical research or clinical pathology services.
Aiforia's core offering is its cloud-based AI platform, which allows users to develop custom AI models tailored to their specific needs. This platform is designed to be user-friendly, requiring no coding skills or specialized hardware. Users simply annotate their images, and Aiforia's neural networks are trained to identify, quantify, or measure the features of interest. This makes the technology accessible to a wide range of professionals, from researchers to clinicians.
The company serves a diverse clientele, including hospitals, research institutions, and pharmaceutical companies. These clients benefit from Aiforia's ability to standardize, accelerate, and reduce costs associated with preclinical and investigational analysis. The AI models developed by Aiforia can be applied to any 2D image, making the technology versatile across various fields and applications.
Aiforia's business model is primarily based on subscription and service fees. Clients pay for access to the cloud-based platform and for custom AI model development services. This recurring revenue model ensures a steady income stream while also allowing for scalability as more clients adopt the technology.
The company recently closed a Series B funding round, which will likely be used to further develop its technology and expand its market reach. This funding is a strong indicator of investor confidence in Aiforia's innovative approach and growth potential.
In summary, Aiforia is at the forefront of integrating AI into image analysis, providing valuable tools for the healthcare and research sectors. Its user-friendly, cloud-based platform and custom AI services make it a versatile and cost-effective solution for a wide range of applications.
Keywords: AI, image analysis, pathology, healthcare, research, cloud-based, custom models, preclinical, clinical, cost-effective.